We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ANAB market cap is 1.01B. The company's latest EPS is USD -5.9893 and P/E is -6.18.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.37M | 3.46M | 3.32M | 9.01M | 7.18M |
| Operating Income | -44.4M | -40.14M | -37.73M | -42.14M | -42.2M |
| Net Income | -44.26M | -39.85M | -37.31M | -42.21M | -43.94M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 8M | 75M | 63.18M | 10.29M | 17.16M |
| Operating Income | -107.43M | -23.88M | -56.81M | -115.15M | -164.41M |
| Net Income | -97.34M | -19.93M | -57.8M | -128.72M | -163.62M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 551.79M | 517.1M | 487.33M | 452.39M | 405.84M |
| Total Liabilities | 360.7M | 368.65M | 366.94M | 364.29M | 358.06M |
| Total Equity | 191.09M | 148.45M | 120.38M | 88.1M | 47.78M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 435.2M | 416.55M | 643.07M | 610.38M | 452.39M |
| Total Liabilities | 30.19M | 19.82M | 286.64M | 348.28M | 364.29M |
| Total Equity | 405.01M | 396.73M | 356.43M | 262.1M | 88.1M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -24.57M | -49.98M | -86.45M | -120.8M | -37.25M |
| Investing | 85.4M | 64.94M | 95.58M | 144.75M | 68.62M |
| Financing | -37.57M | -51.07M | -54.14M | -59.3M | -13.63M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -69.52M | -14.16M | -45.92M | -73.59M | -120.8M |
| Investing | 131.43M | 94.48M | 38.84M | -394.85M | 144.75M |
| Financing | -4.49M | -879k | 252.3M | 44.02M | -59.3M |
| Market Cap | 1.01B |
| Price to Earnings Ratio | -6.18 |
| Price to Sales Ratio | 58.9 |
| Price to Cash Ratio | 28.1 |
| Price to Book Ratio | 11.47 |
| Dividend Yield | - |
| Shares Outstanding | 27.32M |
| Average Volume (1 week) | 295.25k |
| Average Volume (1 Month) | 304.39k |
| 52 Week Change | 111.05% |
| 52 Week High | 38.85 |
| 52 Week Low | 13.36 |
| Spread (Intraday) | 18 (47.37%) |
| Company Name | AnaptysBio Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.anaptysbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
